Abstract Details

Title Serum Glial Fibrillary Acidic Protein and Serum Neurofilament Light Chain in NMOSD and Multiple Sclerosis; a Systematic Review of the Literature and Meta-Analysis

Topic Autoimmune Neurology

Presentation(s) P1 - Poster Session 1 (11:45 AM-12:45 PM)

Poster/Presentation
Number 8-019

Objective This review aims to compare available data on the level of serum GFAP and serum NfL between multiple sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and healthy controls (HCs).

Background There is increasing evidence of serum neurofilament light (NfL) and Glial fibrillary acidic protein (GFAP) measurements in MS and NMOSD patients and lack of a systematic review and meta-analysis to comprehensively assess the role of serum GFAP and serum NfL in MS and NMOSD.

Design/Methods We conducted a systematic search on electronic databases (PubMed, Cochrane Library, GoogleScholar and EMBASE) from inception to August 2024 using the keywords to identify studies that measured serum GFAP and Nfl levels in people with MS and NMOSD. Quality assessment was done using Newcastle-Ottawa Scale (NOS). Statistical analysis was done using RevMan 5.4. Random-effect model was used to pool the effect size with its 95% confidence interval (CI).

Results

Our search yielded 905 studies. A total of 14 studies met our inclusion criteria. The standard mean difference in serum GFAP levels was 0.92 [(0.78-1.05), p <0.05] for NMOSD and 0.50 [(0.03-0.96), p=0.04] for MS, compared to healthy controls, both were statistically significant. Similarly, the standard mean difference in serum NfL levels was 0.81 [(0.67-0.96), p < 0.05] for NMOSD and 0.95 [(0.58-1.32), p < 0.05] for MS, compared to healthy controls, and both were statistically significant.

Conclusions Serum GFAP and NfL may be potential biomarkers for MS and NMOSD, as their values increase in the serum of patients with these conditions.

Authors/Disclosures
Yagya Adhikari, MBBS PRESENTER	Dr. Adhikari has received personal compensation for serving as an employee of Cooper University Hospital.
Sangam Shah (Tribhuvan University, Institute of Medicine)	Dr. Shah has nothing to disclose.
Madhur Bhattatai, MBBS	Dr. BHATTARAI has nothing to disclose.
Amita Paudel	Dr. Paudel has nothing to disclose.
Olga R. Thon, MD (Cooper Neurological Institute)	Dr. Thon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Thon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Thon has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon.
Jesse Thon, MD (Cooper University Hospital)	An immediate family member of Dr. Thon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. An immediate family member of Dr. Thon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. An immediate family member of Dr. Thon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genentech.

��ɫ��

��ɫ��